Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
February 13, 2026 17:00 ET | Source: Ocular Therapeutix, Inc. Ocular to…
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026 16:01 ET | Source: Ocular Therapeutix, Inc. BEDFORD, Mass.,…
